MedTrace Logo

The Oxford Marfan Trial

NCT01949233 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2015-06-09

No results posted yet for this study

Summary

The primary objective of the trial is to estimate the effects of allocation to irbesartan, or doxycycline, or a combination of both irbesartan and doxycycline, compared with placebo, on measures of elastic function of the aorta in people with the Marfan syndrome and enlargement of the aorta.

Conditions

  • Marfan Syndrome

Interventions

DRUG

Irbesartan 150-300mg capsules daily for 6 months

DRUG

Doxycycline 100-200mg capsules daily for 6 months

DRUG

Doxycycline placebo capsules daily for 6 months

DRUG

Irbesartan placebo capsules daily for 6 months

Sponsors & Collaborators

  • Oxford University Hospitals NHS Trust

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • J Colin Forfar, BSc (hons), MA(Oxon), MD, PhD, · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-10-31
Completion
2017-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01949233 on ClinicalTrials.gov